ID   RCH-ACV
AC   CVCL_1851
SY   RCHACV; RCH
DR   BTO; BTO:0003376
DR   EFO; EFO_0002314
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 1760
DR   BioSample; SAMN03473533
DR   BioSample; SAMN10989563
DR   cancercelllines; CVCL_1851
DR   Cell_Model_Passport; SIDM00449
DR   Cosmic; 1130248
DR   Cosmic; 1191705
DR   Cosmic; 2396141
DR   Cosmic; 2396180
DR   Cosmic; 2427703
DR   Cosmic; 2491074
DR   Cosmic-CLP; 1330994
DR   DepMap; ACH-000922
DR   DSMZ; ACC-548
DR   DSMZCellDive; ACC-548
DR   EGA; EGAS00001000978
DR   GDSC; 1330994
DR   GEO; GSM887525
DR   GEO; GSM888607
DR   GEO; GSM931332
DR   GEO; GSM931333
DR   GEO; GSM931334
DR   GEO; GSM1670365
DR   GEO; GSM5137739
DR   GEO; GSM5137765
DR   IARC_TP53; 30150
DR   IGRhCellID; RCHACV
DR   LiGeA; CCLE_152
DR   PharmacoDB; RCHACV_1294_2019
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1851
DR   Wikidata; Q54949486
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1720549;
RX   PubMed=1967982;
RX   PubMed=3455845;
RX   PubMed=9067587;
RX   PubMed=10490826;
RX   PubMed=11843816;
RX   PubMed=16523483;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29786757;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35124168;
RX   PubMed=35354797;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 36 hours (PubMed=3455845); ~30-50 hours (DSMZ=ACC-548).
CC   HLA typing: A*02:01,68:01; B*39:01,44:02; C*05:01,12:03 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=11843816; PubMed=35354797).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg677Cys (c.2029C>T); ClinVar=VCV000950520; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Ala11Thr (c.31G>A); ClinVar=VCV000178860; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Val14Ile (c.40G>A); ClinVar=VCV000012589; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 12766; NSD2; Simple; p.Glu1099Lys (c.3295G>A); ClinVar=VCV000638278; Zygosity=Heterozygous (PubMed=35124168).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.05%; Native American=0.59%; East Asian, North=1.16%; East Asian, South=0%; South Asian=2.04%; European, North=65.94%; European, South=30.22% (PubMed=30894373).
CC   Misspelling: RCH-AVC; Cosmic=1191705; Note=Prior to 2020.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9,14
ST   D16S539: 11
ST   D18S51: 13,16
ST   D19S433: 14
ST   D21S11: 29,31.2
ST   D2S1338: 17,18
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 13,15
ST   FGA: 23,26
ST   Penta D: 9,10
ST   Penta E: 7,11
ST   TH01: 6,8
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C9140; Childhood B acute lymphoblastic leukemia
DI   NCIt; C80347; B acute lymphoblastic leukemia with t(1;19)(q23;p13.3) E2A-PBX1 (TCF3-PBX1)
DI   ORDO; Orphanet_585956; B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_Y458 ! RCH-ADD
SX   Female
AG   8Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 37
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1720549; DOI=10.1073/pnas.88.23.10735;
RA   Ziemin-van der Poel S., McCabe N.R., Gill H.J., Espinosa R. III,
RA   Patel Y., Harden A.M., Rubinelli P., Smith S.D., Le Beau M.M.,
RA   Rowley J.D., Diaz M.O.;
RT   "Identification of a gene, MLL, that spans the breakpoint in 11q23
RT   translocations associated with human leukemias.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10735-10739(1991).
//
RX   PubMed=1967982; DOI=10.1016/0092-8674(90)90657-Z;
RA   Nourse J., Mellentin J.D., Galili N., Wilkinson J., Stanbridge E.J.,
RA   Smith S.D., Cleary M.L.;
RT   "Chromosomal translocation t(1;19) results in synthesis of a homeobox
RT   fusion mRNA that codes for a potential chimeric transcription
RT   factor.";
RL   Cell 60:535-545(1990).
//
RX   PubMed=3455845; DOI=10.1016/0165-4608(86)90055-5;
RA   Jack I., Seshadri R., Garson O.M., Michael P., Callen D.F., Zola H.,
RA   Morley A.A.;
RT   "RCH-ACV: a lymphoblastic leukemia cell line with chromosome
RT   translocation 1;19 and trisomy 8.";
RL   Cancer Genet. Cytogenet. 19:261-269(1986).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=10490826; DOI=10.1038/sj.onc.1202874;
RA   Fu X.-Y., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.;
RT   "EB-1, a tyrosine kinase signal transduction gene, is
RT   transcriptionally activated in the t(1;19) subset of pre-B ALL, which
RT   express oncoprotein E2a-Pbx1.";
RL   Oncogene 18:4920-4929(1999).
//
RX   PubMed=11843816; DOI=10.1046/j.1365-2141.2001.03190.x;
RA   Curry J.D., Glaser M.C., Smith M.T.;
RT   "Real-time reverse transcription polymerase chain reaction detection
RT   and quantification of t(1;19) (E2A-PBX1) fusion genes associated with
RT   leukaemia.";
RL   Br. J. Haematol. 115:826-830(2001).
//
RX   PubMed=16523483; DOI=10.1002/gcc.20317;
RA   Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H.,
RA   Dexter T.J., Ashworth A., Kearney L.;
RT   "Array CGH of fusion gene-positive leukemia-derived cell lines reveals
RT   cryptic regions of genomic gain and loss.";
RL   Genes Chromosomes Cancer 45:554-564(2006).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29786757; DOI=10.1007/s12185-018-2474-7;
RA   Tomoyasu C., Imamura T., Tomii T., Yano M., Asai D., Goto H.,
RA   Shimada A., Sanada M., Iwamoto S., Takita J., Minegishi M., Inukai T.,
RA   Sugita K., Hosoi H.;
RT   "Copy number abnormality of acute lymphoblastic leukemia cell lines
RT   based on their genetic subtypes.";
RL   Int. J. Hematol. 108:312-318(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35124168; DOI=10.1016/j.jsbmb.2022.106068;
RA   Tamai M., Kasai S., Akahane K., Thu T.N., Kagami K., Komatsu C.,
RA   Abe M., Watanabe A., Goi K., Miyake K., Inaba T., Takita J., Goto H.,
RA   Minegishi M., Iwamoto S., Sugita K., Inukai T.;
RT   "Glucocorticoid receptor gene mutations confer glucocorticoid
RT   resistance in B-cell precursor acute lymphoblastic leukemia.";
RL   J. Steroid Biochem. Mol. Biol. 218:106068.1-106068.12(2022).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//